+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine j774 macrophages

Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine j774 macrophages

Journal of Pharmacology and Experimental Therapeutics 326(2): 514-522

Tristetraprolin (TTP) is a trans-acting factor that can regulate mRNA stability by binding to the cis-acting AU-rich element (ARE) in the 3'-untranslated region in mRNAs of certain transiently expressed genes. The best-studied target of TTP is tumor necrosis factor (TNF)-. By binding to ARE, TTP increases the degradation of TNF-alpha mRNA, thereby reducing the expression of TNF-alpha. We examined the effects of cAMP analogs and the cAMP-elevating agents forskolin and beta2-agonists on lipopolysaccharide (LPS)-induced TTP mRNA and protein expression by quantitative real-time reverse transcriptase-polymerase chain reaction and Western blotting in activated macrophages. All of these agents caused a slight increase in LPS-induced expression of TTP mRNA. However, TTP protein levels were significantly reduced when the cells were treated with the combination of LPS and cAMP-elevating agent compared with LPS alone. Proteasome inhibitors MG132 (N-[(phenylmethoxy)-carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide) and lactacystin increased TTP protein levels and abolished the effects of cAMP-enhancing compounds on TTP protein levels. The results suggest that mediators and drugs that enhance intracellular cAMP reduce TTP expression in macrophages exposed to inflammatory stimuli by increasing TTP degradation through the proteasome pathway.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269451

Download citation: RISBibTeXText

PMID: 18469159

DOI: 10.1124/jpet.107.133702

Related references

The modulation of transcobalamin II (TC-II) production by cyclic adenosine 3',5'-monophosphate in the murine macrophage cell line J774: relationship to growth behavior. Journal of Cellular Physiology 126(3): 430-434, 1986

Cyclic adenosine 3',5'-monophosphate in guinea pig cerebral cortical slices. 3. Formation, degradation, and reformation of cyclic adenosine 3',5'-monophosphate during sequential stimulations by biogenic amines and adenosine. Journal of Biological Chemistry 248(3): 860-866, 1973

Fatty acid degradation in Escherichia coli: requirement of cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein for enzyme synthesis. Journal of Bacteriology 117(3): 1178-1183, 1974

Differential effects of dibutyryl cyclic adenosine monophosphate and retinoic acid on the growth, differentiation, and cyclic adenosine monophosphate-binding protein of murine neuroblastoma cells. Cancer Research 47(9): 2417-2424, 1987

Mechanism of the impairment of the glucagon-stimulated phosphoenolpyruvate carboxykinase gene expression by interleukin-6 in rat hepatocytes: Inhibition of the increase in cyclic 3',5' adenosine monophosphate and the downstream cyclic 3',5' adenosine monophosphate action. Hepatology 26(1): 73-80, 1997

Elevation of intracellular cyclic adenosine 3',5'-monophosphate levels in macrophages activated with lipopolysaccharide for tumor cell killing. Chemical and Pharmaceutical Bulletin 39(4): 991-993, 1991

Renal effects of adenosine 3',5'-cyclic monophosphate and dibutyryl adenosine 3',5'-cyclic monophosphate. Evidence for a role for adenosine 3',5'-cyclic monophosphate in the regulation of proximal tubular sodium reabsorption. Journal of Clinical Investigation 50(6): 1231-1240, 1971

Parathyroid hormone is able to enhance cyclic adenosine monophosphate formation without causing an increase in cytoplasmic calcium in osteoblasts. Acta Endocrinologica 129(2): 178-184, 1993

Measurements of cyclic adenosine monophosphate and cyclic guanosine monophosphate levels in polymorphonuclear leukocytes, macrophages, and lymphocytes. Methods in Enzymology 132: 428-434, 1986

An equilibrium study of the cooperative binding of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate to the adenosine cyclic 3',5'-monophosphate receptor protein from Escherichia coli. Biochemistry 19(22): 5124-5130, 1980

Effect of hypocalcemic protein P-MSY obtained from bovine parotid gland on the cyclic adenosine-5'-monophosphate and cyclic guanosine-5'-monophosphate contents of murine thymus and spleen cells. Chemical and Pharmaceutical Bulletin 31(5): 1757-1760, 1983

Adenosine 3':5'-cyclic monophosphate-dependent protein kinase in brown fat from newborn rabbits. Changes in the binding of adenosine 3':5'-cyclic monophosphate after preincubation of the tissue with noradrenaline or incubation of the enzyme with adenosine triphosphate. Biochemical Journal 152(3): 577-582, 1975

High pressure anion exchange chromatographic measurement of cyclic adenosine 3',5'-monophosphate and cyclic (14C) adenosine monophosphate specific activity in myocardium prelabeled with (14C) adenosine. Journal of Biological Chemistry 246(24): 7810-7816, 1971

Effect of N 6 , 2'-O-dibutyryl 3'5'-cyclic adenosine monophosphate, 3', 5',-cyclic adenosine monophosphate and adenosine triphosphate on acetylcholine output from cholinergic nerves in guinea pig ileum. Japanese Journal of Pharmacology 22(1): 33-36, 1972

Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost. Prostaglandins Leukotrienes and Essential Fatty Acids 49(5): 839-845, 1993